NEWS

INTCO Medical has been honored with the JING CHAO AWARDS OF 2025 – ESG Value Listed Company of the Year, recognizing its measurable performance in environmental, social, and governance (ESG) practices and its ability to create long-term, verifiable value. The award, jointly evaluated by leading Chinese financial media and capital market assessment institutions, highlights publicly listed companies that demonstrate transparent governance, sustainable growth models, and responsible corporate citizenship.

For global buyers of medical consumables and institutional partners tracking ESG compliance in supply chains, this recognition offers more than a headline—it provides concrete evidence of operational discipline, sustainability execution, and governance credibility.

Embedding ESG into the Core Business Strategy

As a global manufacturer of medical consumables and rehabilitation products, INTCO Medical has integrated ESG principles into its overall corporate strategy rather than treating sustainability as a separate reporting function. The company publishes structured annual ESG disclosures aligned with regulatory frameworks and investor expectations, enabling stakeholders to track carbon metrics, energy usage, governance mechanisms, and compliance performance year over year.

Inside INTCO Medical’s production facilities, ESG is reflected in process-level decisions. For example, during nitrile glove manufacturing, the company tracks energy consumption per production line and monitors carbon emissions across each stage—from raw material compounding to dipping, curing, chlorination, and packaging. Process engineers review weekly variance reports to identify abnormal energy spikes and conduct root-cause analysis before approving production scale adjustments. These operational reviews are documented and integrated into internal audit cycles.

The company’s systematic ESG approach aligns with global sustainability frameworks such as the United Nations Sustainable Development Goals, ensuring that carbon reduction and responsible production targets are benchmarked against internationally recognized standards.

Advancing Low-Carbon Manufacturing in Medical Consumables

INTCO Medical has actively responded to China’s “Dual Carbon” strategy by upgrading its manufacturing infrastructure and introducing renewable energy solutions across selected facilities. Solar installations, waste heat recovery systems, and optimized water circulation processes have contributed to a continuous reduction in product lifecycle carbon emissions.

In disposable glove production, lifecycle carbon accounting includes not only factory-level emissions but also packaging weight optimization and logistics efficiency improvements. Procurement teams coordinate with raw material suppliers to evaluate upstream emission factors, strengthening supply chain transparency.

Within its portfolio of Disposable Gloves, the company applies material optimization models to reduce compound waste during batch transitions. When mold calibration deviations occur during dipping processes—an issue that can increase material scrap rates—production supervisors suspend line output until calibration passes third-party inspection standards. This discipline minimizes both resource waste and downstream defect risks.

Environmental compliance is reinforced through structured monitoring systems aligned with ISO management standards such as ISO 14001 Environmental Management Systems. Rather than simply displaying certification logos, INTCO Medical conducts internal pre-audit simulations before third-party audits, reviewing wastewater treatment logs, hazardous material storage procedures, and energy intensity reports in advance.

Governance Transparency Backed by Capital Market Recognition

In corporate governance, INTCO Medical operates under a modern enterprise structure that emphasizes board independence, internal controls, and standardized disclosure procedures. Audit committees conduct regular compliance reviews, and financial disclosures are reviewed under multi-layer verification protocols before release.

Over recent years, as ESG evaluation systems in capital markets have matured, the company has maintained strong performance in domestic and international ESG ratings. These evaluations consider not only environmental metrics but also board structure, risk management practices, and shareholder communication transparency.

Industry recognition is supported by broader third-party validation frameworks. Global buyers frequently reference standards from organizations such as the World Health Organization and the U.S. Food & Drug Administration when assessing suppliers. INTCO Medical structures its documentation and compliance reporting to align with such regulatory expectations, particularly for export markets requiring FDA 510(k), CE marking, or other region-specific certifications.

Building Social Responsibility into Daily Operations

ESG performance extends beyond environmental metrics. INTCO Medical’s social responsibility initiatives are embedded into employee management systems, training mechanisms, and community engagement programs.

Employee onboarding includes structured compliance training, production safety workshops, and quality control simulations. During factory visits by overseas clients, inspection routes typically include raw material storage zones, dipping lines, curing ovens, finished goods warehouses, and quality laboratories. Clients are encouraged to review batch traceability systems, defect sampling protocols, and corrective action records.

In quality control labs, random sampling tests measure tensile strength, elongation, and pinhole defect rates according to international standards. If a batch fails AQL inspection, quarantine procedures are triggered immediately, and corrective action documentation is required before production resumes. These operational safeguards reduce supply chain risk for importers concerned about recall exposure.

Beyond internal systems, INTCO Medical participates in public health education initiatives and community welfare programs, supporting healthcare access and local development efforts. Corporate philanthropy projects are documented within annual ESG reports to ensure transparency and measurable outcomes.

Risk Transparency and Long-Term Partnership Approach

Trust in global medical supply chains depends not only on certifications but also on risk disclosure and problem-solving capability. INTCO Medical defines lead times based on production scheduling data and raw material inventory buffers rather than generalized estimates. During periods of raw material volatility, procurement teams provide forecast-based communication to key customers.

In the event of quality deviations, structured after-sales procedures guide response timelines, product return logistics, and compensation evaluation. Payment terms and shipment documentation processes are clarified contractually before production begins, reducing ambiguity for international distributors.

The recognition as JING CHAO AWARDS OF 2025 – ESG Value Listed Company of the Year reflects not only historical achievements but also the operational systems behind them. ESG integration at INTCO Medical is measurable through carbon data, governance records, audit logs, and client inspection transparency.

A Strategic Milestone for Sustainable Industry Transformation

Winning the JING CHAO AWARDS OF 2025 – ESG Value Listed Company of the Year affirms INTCO Medical’s sustained focus on aligning environmental stewardship, social responsibility, and corporate governance with long-term commercial resilience. The award acknowledges structured ESG implementation rather than promotional claims.

As global healthcare systems demand lower-carbon procurement and stricter compliance documentation, manufacturers of medical consumables must demonstrate both technical capability and governance maturity. INTCO Medical’s ESG framework positions the company to support distributors, hospitals, and healthcare networks seeking reliable, sustainable supply partners.